Track AbCellera Biologics Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

AbCellera Biologics Inc. ABCL · Stock Open AbCellera Biologics Inc. in new tab

11.49 USD
EPS
-0.48
P/B
3.57
ROE
-17.30
Beta
1.59
Target Price
18.00 USD
AbCellera Biologics Inc. logo

AbCellera Biologics Inc.

🧾 Earnings Recap – Q3 2026

AbCellera reported Q3 results centered on positive Phase 2 data for ABCL635, with a 4-week placebo-adjusted reduction of 5.3 moderate-to-severe hot flashes per day. The stock was roughly flat after earnings, down 0.3%, indicating a neutral market reaction.

  • ABCL635 reduced daily moderate-to-severe hot flashes by 8.8 from baseline at week 4, versus 3.5 for placebo; the placebo-adjusted reduction was 5.3 events, or 50% of baseline.
  • Hot-flash severity fell by 1.4 points with ABCL635 and 0.3 points with placebo, a 1.1-point placebo-adjusted difference.
  • At week 4, 37% of ABCL635 participants had complete resolution of moderate-to-severe events, versus 2.2% on placebo; 78% had a reduction of more than 75%.
  • Management said the study showed no clear gastrointestinal or liver toxicity signal. Adverse events were numerically more frequent with ABCL635, including headache and fatigue; reported fatigue events were mild.
  • The company said it is committed to advancing ABCL635 into late-stage development next year.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 23, 2027
EPS-0.48
Book Value3.22
Price to Book3.57
Debt/Equity15.14
% Insiders21.736%
Growth
Revenue Growth-0.76%
Estimates
Forward P/E-15.70
Forward EPS-0.73
Target Mean Price18.00

DCF valuation

Model fair value for AbCellera Biologics Inc. (ABCL)
Result
Sign in to run the valuation for ABCL.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
12 analysts · consensus Strong buy · mean target 18.00 USD (low 12.00, high 30.00) · as of 14 Nov 2026
Low 12.00
Mean 18.00
High 30.00
Price 11.49
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

AbCellera Biologics Inc. Logo AbCellera Biologics Inc. Analysis (ABCL)

Canada Health Care Official Website Stock

Is AbCellera Biologics Inc. a good investment? AbCellera Biologics Inc. (ABCL) is currently trading at 11.49 USD. Market analysts have a consensus price target of 18.00 USD. This suggests a potential upside from current levels.

Earnings Schedule: AbCellera Biologics Inc. is expected to release its next earnings report on Feb. 23, 2027. The market consensus estimate for Forward EPS is -0.73.

Investor FAQ

Does AbCellera Biologics Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is AbCellera Biologics Inc.?

AbCellera Biologics Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 23, 2027. The company currently has a trailing EPS of -0.48.

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Exchange Ticker
NMS (United States) ABCL
FRA (Germany) 8QQ.F
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion